Tags: Cancer | non-small cell lung cancer | necitumumab | IMC-11F8 | chemotherapy

New Lung Cancer Drug Works in Trial

Tuesday, 13 Aug 2013 12:06 PM


Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014.
Lilly shares were up 4 percent in premarket trading.
The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone.
"If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement.
The company's stock closed at $54.05 on the New York Stock Exchange on Monday.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
Health-News
Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014. Lilly shares were up 4 percent in premarket trading.The drug, necitumumab or...
non-small cell lung cancer,necitumumab,IMC-11F8,chemotherapy
119
2013-06-13
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved